Kala Pharmaceuticals (KALA) Misses Q4 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. LEVI
2. STZ
3. GOOGL
4. APLD
5. SPCX
6. NVDA
7. SPY
8. TSM
9. MSFT
10. SBUX

Go back to Kala Pharmaceuticals (KALA) Misses Q4 EPS by 9c

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

February 25, 2021 7:00 AM EST

-- Launched EYSUVIS, First and Only Prescription Therapy Approved Specifically for Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease --

-- Progressing Pipeline Programs to Address Front and Back of Eye Diseases --

-- Cash Position and INVELTYS Revenue Expected to Provide Runway Into at Least 4Q 2022; EYSUVIS Revenue Expected to Provide Additional Runway --

-- Conference Call and Webcast at 8:00 a.m. ET

WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ: KALA), a... More